Sands Capital Ventures
Latest statistics and disclosures from Sands Capital Alternatives's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Alamar Biosciences, NU, KVYO, BBNX, SGP, and represent 62.34% of Sands Capital Alternatives's stock portfolio.
- Added to shares of these 10 stocks: Alamar Biosciences (+$115M), Odyssey Therapeutics (+$16M), NU (+$7.4M), CBRS (+$7.3M), CPNG (+$5.5M), KVYO, DASH, TOST, TTAN, SNOW.
- Started 3 new stock positions in Odyssey Therapeutics, CBRS, Alamar Biosciences.
- Reduced shares in these 2 stocks: IOT, DDOG.
- Sands Capital Alternatives was a net buyer of stock by $161M.
- Sands Capital Alternatives has $614M in assets under management (AUM), dropping by 45.67%.
- Central Index Key (CIK): 0001846444
Tip: Access up to 7 years of quarterly data
Positions held by Sands Capital Ventures consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sands Capital Alternatives
Sands Capital Alternatives holds 24 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Alamar Biosciences Common Stock | 18.7 | $115M | NEW | 4.2M | 27.09 |
|
| Nu Hldgs Ord Shs Cl A (NU) | 15.4 | $95M | +8% | 7.1M | 13.36 |
|
| Klaviyo Com Ser A (KVYO) | 9.7 | $59M | +7% | 3.9M | 15.10 |
|
| Beta Bionics (BBNX) | 9.5 | $58M | 3.7M | 15.67 |
|
|
| Spyglass Pharma Com Shs (SGP) | 9.1 | $56M | 2.5M | 22.26 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 4.3 | $26M | 13M | 2.03 |
|
|
| Doordash Cl A (DASH) | 3.8 | $24M | +14% | 128k | 184.53 |
|
| Coupang Cl A (CPNG) | 3.8 | $23M | +31% | 1.3M | 17.37 |
|
| Datadog Cl A Com (DDOG) | 3.4 | $21M | -5% | 81k | 260.36 |
|
| Bioage Labs (BIOA) | 3.1 | $19M | 786k | 24.51 |
|
|
| 10x Genomics Cl A Com (TXG) | 3.0 | $19M | 482k | 38.34 |
|
|
| Samsara Com Cl A (IOT) | 2.7 | $17M | -7% | 516k | 32.43 |
|
| Odyssey Therapeutics Common Stock | 2.7 | $16M | NEW | 875k | 18.71 |
|
| Toast Cl A (TOST) | 1.7 | $10M | +20% | 365k | 27.82 |
|
| Acumen Pharmaceuticals (ABOS) | 1.6 | $9.9M | 3.7M | 2.67 |
|
|
| Servicetitan Shs Cl A (TTAN) | 1.3 | $7.7M | +20% | 109k | 70.71 |
|
| Cerebras Systems Com Cl A (CBRS) | 1.2 | $7.3M | NEW | 33k | 221.00 |
|
| Snowflake Com Shs (SNOW) | 1.0 | $6.2M | +20% | 25k | 254.50 |
|
| Monday SHS (MNDY) | 1.0 | $5.9M | +20% | 82k | 72.39 |
|
| Tarsus Pharmaceuticals (TARS) | 0.9 | $5.3M | 85k | 62.94 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.8 | $4.9M | 725k | 6.81 |
|
|
| Candel Therapeutics (CADL) | 0.7 | $4.2M | 406k | 10.30 |
|
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.7 | $4.1M | +7% | 2.3M | 1.78 |
|
| Figma Class A Com Stk (FIG) | 0.1 | $401k | +21% | 22k | 18.09 |
|
Past Filings by Sands Capital Alternatives
SEC 13F filings are viewable for Sands Capital Alternatives going back to 2021
- Sands Capital Alternatives 2026 Q2 filed Aug. 13, 2026
- Sands Capital Alternatives 2026 Q1 filed May 8, 2026
- Sands Capital Alternatives 2025 Q4 filed Feb. 13, 2026
- Sands Capital Alternatives 2025 Q3 filed Nov. 13, 2025
- Sands Capital Alternatives 2025 Q2 filed Aug. 13, 2025
- Sands Capital Ventures 2025 Q1 filed May 14, 2025
- Sands Capital Ventures 2024 Q4 filed Feb. 13, 2025
- Sands Capital Ventures 2024 Q3 filed Nov. 13, 2024
- Sands Capital Ventures 2024 Q1 filed May 14, 2024
- Sands Capital Ventures 2023 Q3 filed Nov. 14, 2023
- Sands Capital Ventures 2023 Q2 filed Aug. 15, 2023
- Sands Capital Ventures 2023 Q1 filed May 12, 2023
- Sands Capital Ventures 2022 Q4 filed Feb. 13, 2023
- Sands Capital Ventures 2022 Q3 filed Nov. 9, 2022
- Sands Capital Ventures 2022 Q2 filed Aug. 12, 2022
- Sands Capital Ventures 2022 Q1 filed May 13, 2022